Atlas Trials

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Clinical trial NCT04207463 · UNKNOWN

Trial details

NCT number
NCT04207463
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
Start date
2020-06-03
Primary completion
2020-12-31
Enrollment
150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.